ORLANDO — In this video exclusive, Stephen B. Hanauer, MD, professor of medicine at Northwestern University Feinberg School of Medicine, Chicago, and co-chair of AIBD 2016, discusses his presentation on where new IBD therapies will fit within clinical practice in the future, during which he called for a “culture shift” in how stakeholders work together.
“[I] advocate earlier therapy in both ulcerative colitis and in particular Crohn’s disease, and head-to-head comparisons so that we can really begin to position these therapies more effectively ... in clinical practice, and also convince pharmacy benefit managers of their real importance,” he said.
Hanauer SB. “How will future therapeutic pathways change for ulcerative colitis and Crohn's disease?” Presented at: Advances in Inflammatory Bowel Diseases; Dec. 8-10, 2016; Orlando, Fla.
Disclosures: Hanauer reports financial relationships with AbbVie, Actavis, Amgen, Arena, Astra Zeneca, Baxter, Boehringer Ingelheim, Bristol-Myers Squibb, Catabasis, Celltrion, Cubist, Ferring, Genentech, Entera Health, GlaxoSmithKline, Hospira, Janssen, Lilly, Novartis, Novo Nordisk and Pfizer.